Image

Global Acute Myeloid Testing Market - Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Dec 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Dec 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Acute Myeloid Testing Market, By Biomarker Type (Genetic AML Biomarker, Epigenetic AML Biomarker, Proteomic AML Biomarker), Product and Service (Services, Assay Kits), Technology (PCR, IHC, NGS, Cytogenetics, Others), End User (Clinical Laboratories, Hospitals, Academic and Research Institutes, Cancer Diagnostic Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Acute Myeloid Testing Market Global Acute Myeloid Testing Market Analysis and Insights

Data Bridge Market Research analyses that the acute myeloid testing market to account USD 1,385.35 million by 2029 and growing at a CAGR of 13.70% in the forecast period of 2022-2029.

Acute myeloid testing is a type of a test in which the sample of your blood is examined under a microscope. It usually checks the shape, number, and size of white blood cells, and airs for immature white blood cells called blasts.

The rising incidence of acute myeloid a type of cancer is the prime factor responsible for the growth of the acute myeloid testing market in the forecast period of 2022 to 2029. The rise in the incidence of the aging population in combination with growing population prevalence for acute myeloid leukemia are also the major factors enhancing the growth rate for acute myeloid testing market

However, high cost for acute myeloid tests, stringent regulatory policies will act as market restraints for the acute myeloid testing market, whereas the low detection rates are expected to hamper the acute myeloid testing market.

The increasing number of population and rapid rise in the research and development activities can create new opportunities for acute myeloid testing market.

This acute myeloid testing market  report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization,  market   share, impact of domestic and localized market   players, analyses opportunities in terms of emerging revenue pockets, changes in  market   regulations, strategic market   growth analysis, market   size, category market   growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the  market  . To gain more info on acute myeloid testing market contact Data Bridge market   Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Acute Myeloid Testing Market Scope and market Size

The acute myeloid testing market is segmented on the basis of biomarker type, product and service, technology and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market   overview and market   insights to help them in making strategic decisions for identification of core market applications.

  • Based on biomarker type, the acute myeloid testing market is segmented into genetic acute myeloid leukemia (AML) biomarker, epigenetic acute myeloid leukemia (AML) biomarker, and proteomic acute myeloid leukemia (AML) biomarker.  Genetic AML biomarker segment has been further segmented into FLT3, NPM1, TP53, MU-AML and others. Epigenetic AML biomarker has also been segmented into IDH1/2, TET and DNMT3A. Proteomic AML biomarker has been segmented as HNRH1, CALR, FIBA and HSP.
  • Based on the product and service, the acute myeloid testing market is segmented into services and assay kits.
  • Based on technology, the acute myeloid testing market is segmented into market has been segmented into PCR (Polymerase Chain Reaction), IHC (Immunohistochemistry), NGS (Next-Generation Sequencing), cytogenetics and others.
  • Acute myeloid testing market has also been segmented on the basis of end user, it is categorized as clinical laboratories, hospitals, academic and research institutes, cancer diagnostic institutes and others.

Acute Myeloid Testing Market Country Level Analysis

The acute myeloid testing market is analyzed and market size insights and trends are provided by country, biomarker type, product and service, technology and end user as referenced above.

The countries covered in the acute myeloid testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the acute myeloid testing market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the large scale prevalence of the target disorder in the region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the growing volume of patients suffering from this disorder increasing in the region along with the focus of established players to expand their prevalence in this region.

The country section of the acute myeloid testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The acute myeloid testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for acute myeloid testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the acute myeloid testing market. The data is available for historic period 2010 to 2020.

Competitive Landscape and Global Acute Myeloid Testing Market Share Analysis

The acute myeloid testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to acute myeloid testing market.

The major players operating in the acute myeloid testing market report are NeoGenomics Laboratories, Inc., QIAGEN, Invivoscribe, Inc., Illumina, Inc., ArcherDx, Inc., ARUP Laboratories, ASURAGEN, INC., Mayo Foundation for Medical Education and Research, Laboratory Corporation of America Holdings, Dr Lal PathLabs, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Cancer Genetics Inc., and SkylineDx B.V., among others.


SKU-
Why Choose Us


Frequently Asked Questions